These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32616870)

  • 1. Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer.
    Fujiwara A; Funaki S; Fukui E; Kimura K; Kanou T; Ose N; Minami M; Shintani Y
    Sci Rep; 2020 Jul; 10(1):10900. PubMed ID: 32616870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer.
    Fujiwara A; Shintani Y; Funaki S; Kawamura T; Kimura T; Minami M; Okumura M
    Lung Cancer; 2017 Apr; 106():8-16. PubMed ID: 28285699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy.
    Kurita Y; Araya J; Minagawa S; Hara H; Ichikawa A; Saito N; Kadota T; Tsubouchi K; Sato N; Yoshida M; Kobayashi K; Ito S; Fujita Y; Utsumi H; Yanagisawa H; Hashimoto M; Wakui H; Yoshii Y; Ishikawa T; Numata T; Kaneko Y; Asano H; Yamashita M; Odaka M; Morikawa T; Nakayama K; Kuwano K
    Respir Res; 2017 Jun; 18(1):114. PubMed ID: 28577568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirfenidone promotes the levels of exosomal miR-200 to down-regulate ZEB1 and represses the epithelial-mesenchymal transition of non-small cell lung cancer cells.
    Liu J; Cao L; Li Y; Deng P; Pan P; Hu C; Yang H
    Hum Cell; 2022 Nov; 35(6):1813-1823. PubMed ID: 36002606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system.
    Krämer M; Markart P; Drakopanagiotakis F; Mamazhakypov A; Schaefer L; Didiasova M; Wygrecka M
    Cell Signal; 2020 Jan; 65():109432. PubMed ID: 31693876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirfenidone inhibits TGF-β1-induced metabolic reprogramming during epithelial-mesenchymal transition in non-small cell lung cancer.
    Zhang S; Wang Y; Luo D; Cheng Z; Zeng Q; Wang G; Chen M; Zhang S; Luo P
    J Cell Mol Med; 2024 Feb; 28(3):e18059. PubMed ID: 38140828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling.
    Shintani Y; Fujiwara A; Kimura T; Kawamura T; Funaki S; Minami M; Okumura M
    J Thorac Oncol; 2016 Sep; 11(9):1482-92. PubMed ID: 27287412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta.
    Aboulkheyr Es H; Zhand S; Thiery JP; Warkiani ME
    Integr Biol (Camb); 2020 Jul; 12(7):188-197. PubMed ID: 32638026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary fibroblasts induce epithelial mesenchymal transition and some characteristics of stem cells in non-small cell lung cancer.
    Shintani Y; Abulaiti A; Kimura T; Funaki S; Nakagiri T; Inoue M; Sawabata N; Minami M; Morii E; Okumura M
    Ann Thorac Surg; 2013 Aug; 96(2):425-33. PubMed ID: 23773734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer.
    Takatsu F; Suzawa K; Tomida S; Thu YM; Sakaguchi M; Toji T; Ohki M; Tsudaka S; Date K; Matsuda N; Iwata K; Zhu Y; Nakata K; Shien K; Yamamoto H; Nakayama A; Okazaki M; Sugimoto S; Toyooka S
    J Mol Med (Berl); 2023 Dec; 101(12):1603-1614. PubMed ID: 37831111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts.
    Mediavilla-Varela M; Boateng K; Noyes D; Antonia SJ
    BMC Cancer; 2016 Mar; 16():176. PubMed ID: 26935219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3).
    Wu C; Lin H; Zhang X
    Int Immunopharmacol; 2019 Sep; 74():105700. PubMed ID: 31228816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation.
    Vu TN; Chen X; Foda HD; Smaldone GC; Hasaneen NA
    Respir Res; 2019 Sep; 20(1):206. PubMed ID: 31511015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
    Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer.
    Bremnes RM; Dønnem T; Al-Saad S; Al-Shibli K; Andersen S; Sirera R; Camps C; Marinez I; Busund LT
    J Thorac Oncol; 2011 Jan; 6(1):209-17. PubMed ID: 21107292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifibrotic Agent Pirfenidone Suppresses Proliferation of Human Pancreatic Cancer Cells by Inducing G0/G1 Cell Cycle Arrest.
    Usugi E; Ishii K; Hirokawa Y; Kanayama K; Matsuda C; Uchida K; Shiraishi T; Watanabe M
    Pharmacology; 2019; 103(5-6):250-256. PubMed ID: 30731453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer.
    Zhou P; Du X; Jia W; Feng K; Zhang Y
    Signal Transduct Target Ther; 2024 Jun; 9(1):151. PubMed ID: 38910148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo.
    Li C; Rezov V; Joensuu E; Vartiainen V; Rönty M; Yin M; Myllärniemi M; Koli K
    Sci Rep; 2018 Jul; 8(1):10070. PubMed ID: 29968778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression.
    Kanaji N; Yokohira M; Nakano-Narusawa Y; Watanabe N; Imaida K; Kadowaki N; Bandoh S
    Respir Res; 2017 Jun; 18(1):118. PubMed ID: 28619066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.